- Home
- GPRE vs ABUS Comparison
GPRE vs ABUS Comparison
Compare GPRE & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRE
- ABUS
- Stock Information
- Founded
- GPRE 2004
- ABUS 2005
- Country
- GPRE United States
- ABUS United States
- Employees
- GPRE N/A
- ABUS N/A
- Industry
- GPRE Major Chemicals
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- GPRE Industrials
- ABUS Health Care
- Exchange
- GPRE Nasdaq
- ABUS Nasdaq
- Market Cap
- GPRE 631.4M
- ABUS 711.2M
- IPO Year
- GPRE N/A
- ABUS N/A
- Fundamental
- Price
- GPRE $11.17
- ABUS $4.41
- Analyst Decision
- GPRE Hold
- ABUS Strong Buy
- Analyst Count
- GPRE 7
- ABUS 2
- Target Price
- GPRE $8.50
- ABUS $5.00
- AVG Volume (30 Days)
- GPRE 2.0M
- ABUS 927.8K
- Earning Date
- GPRE 11-11-2025
- ABUS 11-05-2025
- Dividend Yield
- GPRE N/A
- ABUS N/A
- EPS Growth
- GPRE N/A
- ABUS N/A
- EPS
- GPRE N/A
- ABUS N/A
- Revenue
- GPRE $2,397,101,000.00
- ABUS $15,416,000.00
- Revenue This Year
- GPRE N/A
- ABUS $138.02
- Revenue Next Year
- GPRE N/A
- ABUS N/A
- P/E Ratio
- GPRE N/A
- ABUS N/A
- Revenue Growth
- GPRE N/A
- ABUS 53.23
- 52 Week Low
- GPRE $3.14
- ABUS $2.71
- 52 Week High
- GPRE $14.04
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- GPRE 59.41
- ABUS 54.87
- Support Level
- GPRE $8.93
- ABUS $4.10
- Resistance Level
- GPRE $12.31
- ABUS $4.65
- Average True Range (ATR)
- GPRE 0.66
- ABUS 0.21
- MACD
- GPRE 0.20
- ABUS -0.02
- Stochastic Oscillator
- GPRE 68.13
- ABUS 58.94
About GPRE Green Plains Inc.
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.